OD-OS Inc.
BERLIN, GERMANY AND SAN FRANCISCO, CALIFORNIA – OD-OS,
developer of Navigated Retina Laser Therapy, announced today the
appointment of Peter Falzon as Chief Commercial Officer of OD-OS
and President of OD-OS, Inc. In this newly created position, Mr.
Falzon will lead the global market introduction of the NAVILAS®
retina navigation therapy solution as well as the U.S. business for
OD-OS.
“Peter brings significant industry experience to OD-OS, as well as a deep
understanding of international markets. We are confident in his ability to
build the commercial side of our business and he will drive the ophthalmic
community to adopt new and better methods for treating retina disease,”
said Winfried Teiwes, CEO of OD-OS.
Mr. Falzon joins OD-OS with a comprehensive career working for leading
medical device manufacturers that develop laser technologies for ophthalmic
and aesthetic applications. These companies, in order of recent post are
Osyris Medical, Ellex Medical, Cutera, Inc. and Coherent, Inc. In these
companies Mr. Falzon has achieved many notable accomplishments,
including: holding senior management positions of CEO, VP of Business
Development, VP of International Business, VP of Marketing, and President of
Japan; led multiple company acquisitions; established direct and distributor
sales channels world-wide; assisted in IPO; and developed senior
management teams to lead global business strategy and operations.
Mr. Falzon holds a Bachelor of Science with a double major in Economics and
Japanese Studies from the University of Michigan and subsequently studied
Economics and Japanese language at Nanzan University of Nagoya, Japan.
“OD-OS has developed a true breakthrough in retina therapy, which I am
very excited to lead the introduction of. Retina physicians will now be able to
treat with more accuracy and safety,” says Mr. Falzon. “Having seen several
live treatments, it is clear that NAVILAS® will establish a new standard of
care for diabetic patients.”
The development of Navigated Retina Laser Therapy has taken place over the
past five years and has recently been FDA cleared and CE approved. The
device, NAVILAS®, employs both imaging and laser technologies into one
integrated system, which allows for seamless diagnosis and treatment of
retina diseases. NAVILAS® imaging capabilities include four modalities that
allow the physician to diagnose and plan the laser procedure with a full view
of the retina. This is in comparison to conventional laser procedures, which
only offer viewing through a slit lamp. Patients will benefit by having a much
faster, more precise and more comfortable treatments. The NAVILAS system
is now available to U.S. and European physicians.
OD-OS currently has offices in Teltow, Germany and Dallas, Texas and will
soon be opening its U.S. headquarters in San Francisco, CA.
About OD-OS
OD-OS is an ISO 9001 and ISO 13485 certified medical device company
headquartered in Teltow/Berlin, Germany. Its US operation, responsible for
marketing, sales and support, is located Grapevine/Dallas, Texas.
OD-OS is a subsidiary of SensoMotoric Instruments (SMI), the technology
leader in eye tracking and registration solutions for refractive laser surgery.
Over the past 15 years, SMI has supplied technology to most major
refractive laser manufacturers.
In 2008, after more than 4 years of development creating Retina Navigation
within SMI, the core development team was spun-out into OD-OS and
charged with resources and ophthalmic industry experts to bring Retina
Navigation with its first product, NAVILAS®, to the market. For more
information visit www.od-os.com or in the US call 1 (877) 628-6367 or
Europe at +49 (3328) 31 282-100.